Navigation Links
Cancer stem cells suppress immune response against brain tumor
Date:1/15/2010

HOUSTON - Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

The researchers demonstrate that this subset of tumor cells, also known as cancer stem cells, stifles the immune response in a variety of ways, but that the effect can be greatly diminished by encouraging the stem cells to differentiate into other types of brain cell.

"We've known for years that glioblastoma and cancer patients in general have impaired immune responses," said senior author Amy Heimberger, M.D., an associate professor in M. D. Anderson's Department of Neurosurgery. "Our research uncovers an important mechanism that shows how that happens. The cancer stem cells inhibit T cell response, and it is these T cells that recognize and eradicate cancer."

Definitions of cancer stem cells vary. To meet the researchers' definition, the cells had to express a marker called CD133, form neurospheres (little round balls) in culture, and be able to recreate glioblastoma multiforme when injected into the brain of a mouse. They also had to be capable of differentiating into specific types of brain cells - neurons, astrocytes and glial cells.

Glioblastoma stem cells have been implicated in tumor resistance to chemotherapy and radiation, and are the believed to be responsible for the relentless recurrence of the disease, said first author Jun Wei, Ph.D., an instructor in the Department of Neurosurgery.

Wei explained that the glioblastoma stem cells suppress T cell response three different ways by:

  • Producing immunosuppressive cytokines that prevent the responses of T cells.
  • Inducing some T cells to become regulatory T cells, which act as brakes on the immune response.
  • Killing T cells via apoptosis, or programmed cell suicide. This is accomplished via the immunosuppressive protein B7-H1 in the stem cells directly contacting the T cells or by secretion of Galectin-3.

Wei said this immunosuppressive effect was reversed when the team placed the undifferentiated glioma stem cells in a culture medium that causes them to differentiate into the three types of neural cell.

"There are multiple research groups around the country, including ours, trying to develop vaccines or other immunotherapeutics against glioma stem cells," Heimberger said. "Now we have to be cognizant that the stem cell may deliver a fatal blow back to the immune system, which will help us understand how to design immune-based therapies."

New drugs or combination therapies are needed, because after decades of research, little progress has been made in treating glioblastoma multiforme. With the best of care patients survive an average of 14 months.

STAT3 pathway inhibits T cell response

In a separate paper in the Jan. 15 issue of Molecular Cancer Therapeutics, the research team also reports that the STAT3 signaling pathway is highly active in glioblastoma stem cells and suppresses immune system response.

Heimberger said the STAT3 molecule is known to induce cancer proliferation and survival migration and invasion, growth of new blood vessels, and immunosuppression.

Inhibiting STAT3, either by silencing it with small interfering RNA or by treatment with an experimental drug called WP1066, reactivates the immune response.

"We showed that if you treat the cancer stem cells with an inhibitor of STAT3, you can restore T cell proliferation and the ability of those cells to make pro-inflammatory cytokines," Heimberger said.

While the response is powerful it is not complete, so the researchers conclude there a STAT3-independent pathway is also at work in mediating immune suppression.

Research continues on how the inhibitors work, and whether they cause the stem cell differentiation that the team has shown reverses immune suppression.

The experimental drug WP1066 was developed by Waldemar Priebe, Ph.D., professor in M. D. Anderson's Department of Experimental Therapeutics. The drug has been shown to inhibit STAT3 in mice and reverse the immune suppression caused by cancer stem cells.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Gene Linked to Schizophrenia May Reduce Cancer Risk
2. Florida Brain Tumor Association & Moffitt Cancer Center Presents: The Bridge to Hope
3. Incorrect Cell Lines Used for Worldwide Cancer Research
4. Statewide Outreach & Information Service Program Operated by Northern California Cancer Center to End
5. Three Pioneering Ideas in Cancer Research Granted Prestigious Damon Runyon-Rachleff Innovation Awards
6. Lung cancer conference leaders honor Paul A. Bunn Jr., M.D.
7. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
8. The first map of colon cancer in Spain is published
9. Stress on Cells Can Turn Them Cancerous
10. Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative
11. Therapy May Relieve Breast Cancer Surgery Complication
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer stem cells suppress immune response against brain tumor
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... STAT courier ... to be a convenient service for Texas, they are expanding their presence in Dallas. ... a hiring spree that will bring new jobs to the Dallas and Forth Worth ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Allergy Diagnostics Market: Scope and Methodology ... used to determine the presence of allergens such ... in the samples by determining the presence of ... on global allergy diagnostics market, analyzes the current ... consists of an executive summary that provides information ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... 8, 2016 True Health Diagnostics today ... laboratory services and management expertise to hospital systems ... allowing more doctors and patients to benefit from ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... under pressure to contain costs, have struggled to ...
Breaking Medicine Technology: